Peficitinib

Drug Profile

Peficitinib

Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Adamantanes; Amides; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Astellas Pharma completes a phase I trial in pharmacokinetics trial in Japan (PO) (NCT02603497)
  • 01 Sep 2016 Astellas Pharma completes a phase I pharmacokinetics trial in Japan (PO) (NCT02586194)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top